Safety and tolerability of first‐line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma

BACKGROUND: Advanced or metastatic esophageal squamous cell carcinoma (ESCC) is associated with poor prognosis; new first‐line systemic treatment options are needed. Combining immuno‐oncology therapies with standard chemotherapy may represent a promising approach for the treatment of solid tumors. R...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Dae Ho, Kim, Hye Ryun, Keam, Bhumsuk, Kato, Ken, Kuboki, Yasutoshi, Gao, Haiyan, Yovine, Alejandro, Robbins, Scott H., Ahn, Myung‐Ju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469840/
https://www.ncbi.nlm.nih.gov/pubmed/37489066
http://dx.doi.org/10.1002/cam4.6260

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469840/
https://www.ncbi.nlm.nih.gov/pubmed/37489066
http://dx.doi.org/10.1002/cam4.6260

Ejemplares similares